These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 31928627)
1. Trk receptor tyrosine kinases in metastasis and cancer therapy. Regua AT; Doheny D; Arrigo A; Lo HW Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627 [TBL] [Abstract][Full Text] [Related]
2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review. El-Nassan HB; Al-Qadhi MA Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881 [TBL] [Abstract][Full Text] [Related]
4. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Federman N; McDermott R Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968 [No Abstract] [Full Text] [Related]
5. Larotrectinib for the treatment of TRK fusion solid tumors. Laetsch TW; Hawkins DS Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734 [No Abstract] [Full Text] [Related]
6. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189 [TBL] [Abstract][Full Text] [Related]
7. Inhibiting TRK Proteins in Clinical Cancer Therapy. Lange AM; Lo HW Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282 [TBL] [Abstract][Full Text] [Related]
8. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine. Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202 [TBL] [Abstract][Full Text] [Related]
9. Identifying patients with NTRK fusion cancer. Solomon JP; Benayed R; Hechtman JF; Ladanyi M Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428 [TBL] [Abstract][Full Text] [Related]